Physician profile
Christopher Scott Evans
NPI 1326571258
$925.50
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $144 · 2023: $498 · 2024: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $375 · Food and Beverage: $219 · Consulting Fee: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $375.00 |
| Food and Beverage | $219.36 |
| Consulting Fee | $187.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Molecular Systems, INC. | $562.50 | 2023-2024 | |
| Gilead Sciences, INC. | $245.66 | 2022-2024 | |
| Theratechnologies INC. | $45.95 | 2022 | |
| Zoll Medical Corporation | $28.47 | 2022 | |
| Roche Diagnostics Corporation | $27.03 | 2024 | |
| Viiv Healthcare Company | $15.89 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.